Administration and Corporate Management
Submitted by Anonymous (not verified) on 1 September 2025 - 10:40
Administration and Corporate Management
Organisation chart: Administration and Corporate Management
Submitted by Anonymous (not verified) on 1 September 2025 - 8:26
Organisation chart: Administration and Corporate Management
Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 21:49
Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 15:20
Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised
Minutes of the CAT meeting 11-13 June 2025
Submitted by Anonymous (not verified) on 29 August 2025 - 14:16
Minutes of the CAT meeting 11-13 June 2025
Human medicines European public assessment report (EPAR): Nubeqa, darolutamide, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 12:30
Human medicines European public assessment report (EPAR): Nubeqa, darolutamide, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised
List of centrally authorised products with safety-related changes to the product information
Submitted by Anonymous (not verified) on 29 August 2025 - 11:40
List of centrally authorised products with safety-related changes to the product information
Human medicines European public assessment report (EPAR): Rivaroxaban Accord, rivaroxaban, Date of authorisation: 16/11/2020, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 28 August 2025 - 16:10
Human medicines European public assessment report (EPAR): Rivaroxaban Accord, rivaroxaban, Date of authorisation: 16/11/2020, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 20, Status: Authorised
Submitted by Anonymous (not verified) on 28 August 2025 - 16:00
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 20, Status: Authorised
Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 28 August 2025 - 9:41
Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 13, Status: Authorised